The clinical efficacy of Rev-Eyes in reversing the effects of pupillary dilation.
Pupillary dilation to perform binocular indirect ophthalmoscopy has become a routine part of optometric practice. Many patients find the resulting photophobia and incapacity of near vision to be an inconvenience. Rev-Eyes (0.5% dapiprazole HCl) is a new alpha-antagonist reported to reverse the effects of pupillary dilation in approximately one hour. This study was designed to evaluate the usefulness of Rev-Eyes in a routine clinical setting. Seventy-nine subjects free of eye disease that ranged in age from 21 to 40 years received 0.5% proparacaine, 2.5% phenylephrine, and 1.0% tropicamide in each eye. Rev-Eyes was administered to 61 subjects. Eighteen control subjects received 5% NaCl. Effects on pupil diameter, accommodation, and distance and near visual acuity were measured. Conjunctival vasodilation, corneal stippling, patient comfort, and intraocular pressure (IOP) were also evaluated. Our results confirm that a statistically significant reduction in pupil diameter is achieved 60 minutes after installation of Rev-Eyes. However, no significant improvement was obtained in any of the other functional aspects measured Our data suggest limited utility for Rev-Eyes with a young population. The recovery rate of near visual acuity and amplitude of accommodation is identical with or without Rev-Eyes.